The STIKO recommends vaccination against dengue with the vaccine Qdenga as a travel vaccination (R) for individuals over the age of 4 years who have a history of a prior laboratory-confirmed dengue virus infection and who are travelling to a dengue-endemic region where they will have an increased risk of exposure (e.g., 2 prolonged stay, current outbreak event). Prior to travel, a full vaccination series should be completed (i.e., 2 vaccine doses at a minimum interval of 3 months).
The data for individuals who have not previously had a dengue virus infection (“dengue-naïve”) are very limited at present. The STIKO therefore does not currently provide a general vaccine recommendation for dengue-naïve individuals. If, after a detailed medical consultation, vaccination is considered for a dengue-naïve individual in line with the licensure, the potential vaccinee should be informed that the risk of infection intensification in the event of a future infection cannot be ruled out. The currently available data for dengue-naïve individuals could not demonstrate any protection against DENV-3 and -4-associated disease following vaccination. If the vaccination nevertheless takes place, a full vaccination series (i.e., 2 vaccine doses at a minimum interval of 3 months) must be completed prior to departure.
Individuals who have a history of a laboratory-confirmed dengue virus infection and who perform targeted activities with the dengue viruses outside endemic regions (e.g., in research institutions or laboratories), should receive a full vaccine series (i.e., 2 vaccine doses at a minimum interval of 3 months) as an occupationally indicated vaccination (B).
- Recommendation
- Europe
- Germany
- Qdenga
- Dengue
